The global cisatracurium besylate injection market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Cisatracurium besylate injection is a non-depolarizing skeletal neuromuscular blocking agent with an intermediate onset to facilitate non-emergency endotracheal intubation and to provide skeletal muscle relaxation during surgery. The global market is growing due to the increasing number of surgical procedures globally. According to PubMed, around 234.2 million major surgical procedures are performed every year globally. The increasing awareness among individuals about chronic diseases and the availability of advanced treatments is also driving the growth of the market. The supportive government initiatives, as well as huge investment by major manufacturers for research and development, are also driving the growth of the global cisatracurium besylate injection market.
The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new drug launches, to stay competitive in the market. For instance-
- In September 2020, Zydus Group received USFDA approval to market Cisatracurium Besylate injection. The drug will be manufactured at the Liva plant (Vadodara) of Zydus Group.
- In September 2020, USFDA approved an abbreviated new drug application for cisatracurium besylate USP 20 mg/10mL named ‘Nimbex’, which is indicated to facilitate tracheal intubation and provides skeletal muscle relaxation during surgery or mechanical ventilation.
- In May 2020, AuroMedics Pharma LLC received USFDA approval to manufacture and market Cisatracurium Besylate Injection USP, 20 mg/10mL in multiple-dose vials.
(Get 15% Discount on Buying this Report)
Get Sample Copy of Cisatracurium Besylate Injection Market at: https://orionmarketreports.com/request-sample/?id=104581&submit=Request+Sample%0D%0A
Market Coverage
- The market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Application
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– B. Braun Melsungen AG, BD, Baxter, Pfizer Inc., and Fresenius Kabi AG, among others.
A full report Cisatracurium Besylate Injection Market of is available at: https://orionmarketreports.com/cisatracurium-besylate-injection-market/104581/
Global Cisatracurium Besylate Injection Market Report by Segment
By Application
- Hospital
- Clinics
- Recovery Center
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
